Welcome!

News Feed Item

Berg And The Parkinson's Institute And Clinical Center Announce Key Clinical Study Focused On Game-changing Innovations In Parkinson's Disease Biomarker Discovery

- Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets

FRAMINGHAM, Massachusetts and SUNNYVALE, California, Feb. 18, 2014 /PRNewswire/ -- Berg and the Parkinson's Institute and Clinical Center today announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson's disease. Using Berg's Interrogative Biology™ platform to analyze multi-omic tissue samples (skin fibroblasts, blood, urine) supplied by the Parkinson's Institute, this collaboration will identify the differences between healthy and diseased tissues in an effort to unravel the mysteries of Parkinson's disease. Berg and the Parkinson's Institute together are the first teams to approach biomarker discovery by looking at proteomics, metabolomics, and lipidomics, in addition to clinical data, simultaneously in human patients and controls from the same cohort.

The new clinical study launched at the Parkinson's Institute and Clinical Center will collect urine, blood, and other relevant tissue samples from people living with Parkinson's disease. These materials will be used to validate biomarker candidates identified previously from the collaboration. Most importantly, this will represent a first in merging patients' molecular and clinical information to develop profiles that will drive the development of biomarkers.

Berg is a biopharmaceutical company committed to uncovering health solutions through a data-driven, biological research approach. The Parkinson's Institute is America's only independent, non-profit organization that brings together world-class care, laboratory research, clinical research, and clinical trials for Parkinson's disease under one roof.

"This partnership harnesses the exceptional clinical expertise and superior research resources of the Parkinson's Institute, along with Berg's unique ability to integrate patient-specific molecular data with clinical and demographic information," said Niven R. Narain, Co-Founder, President and Chief Technology Officer of Berg. "This new and exciting phase of our collaboration has the potential to create a number of game-changing innovations to better diagnose and manage Parkinson's disease."

Parkinson's disease is a progressive movement-related disorder of the central nervous system. It is estimated that there are approximately one million Americans living with Parkinson's. Each year, 50,000 new cases are diagnosed, and this rate is expected to rise with the aging baby boomer population. A clear understanding of Parkinson's and its underlying pathophysiology continues to be elusive as a result of the disease's complexity and a lack of predictive capability among existing models.

The expectation for this partnership is that it will help lead to a greater understanding of Parkinson's disease and the development of new tools that can change its course.

"Through our collaboration with Berg, we hope to identify predictors for the disease and potential new drug targets. Armed with this information, we will be able to better diagnose and develop therapies that can treat and perhaps even halt the neurological damage caused by Parkinson's, " said Birgitt Schuele, M.D., Director of Gene Discovery and Stem Cell Modeling at the Parkinson's Institute. "This collaboration is very exciting. Our discoveries have the potential to change the way we think about and approach Parkinson's disease."

One fundamental and defining contribution of the Berg-Parkinson's Institute collaboration will be to provide hallmark insights into disease pathophysiology.

"With diseases like cancer and diabetes, we at least have a foundational map and understanding of their pathways. Our challenge with most central nervous system (CNS) diseases is that there is a gross lack of understanding of the molecular pathways and drivers of disease pathophysiology. The anchor points are just not as clear as they are with other disease states," said Paula P. Narain, CNS Disease Program Lead at Berg. "This collaboration will lead to insights into disease mechanisms that will provide a solid foundation for biomarker and therapeutic candidate discovery. Berg is confident that the combination of tissue samples and expertise from the Parkinson's Institute, together with their award-winning Interrogative Biology™ platform, will usher in a paradigm shift in Parkinson's disease."

To learn more about Parkinson's disease, please visit the Parkinson's Institute at ThePI.org. To learn more about Berg, please visit BergPharma.com.

About the Berg Interrogative Biology™ Platform
Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

About Berg
Berg, the namesake of Carl Berg, is a biopharmaceutical company and parent company to Berg Pharma, Berg Biosystems and Berg Diagnostics. Our research focus seeks to understand how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow. For additional information, visit http://www.bergpharma.com/.

About the Parkinson's Institute and Clinical Center
Two and a half decades ago, a dedicated group of Parkinson's disease experts set out to create a better way to research and provide care for Parkinson's disease. We would go beyond your standard doctor-patient relationship. Patients would become partners in developing their care plans, improving their quality of life, and discovering new strategies to confront and manage their disease. Compassionate care would work hand in hand with cutting-edge research to seek answers, develop new therapies and treatments, and ultimately work toward a cure. Our result was the Parkinson's Institute and Clinical Center. Along the way, we have built something that's thoroughly unique. Our Institute is a place where people living with Parkinson's can both pursue their care and play an important role in research that will undoubtedly continue to change the landscape of Parkinson's science and medicine. We are America's only independent nonprofit organization combining world-class care, clinical research, and laboratory research for Parkinson's disease under one roof. By virtue of our design, we are uniquely equipped to provide the best care, accelerate promising science, and perhaps most important—integrate the two and everything in between. It's what we now call Our Virtuous Circle and people living with Parkinson's and their loved ones are at the center of all that we do.

Connect with the Parkinson's Institute:
www.ThePI.org
www.Facebook.com/PDpartner
www.Twitter.com/PDpartner

Contact: Chris Wahlers, +1-212-880-5293, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A critical component of any IoT project is what to do with all the data being generated. This data needs to be captured, processed, structured, and stored in a way to facilitate different kinds of queries. Traditional data warehouse and analytical systems are mature technologies that can be used to handle certain kinds of queries, but they are not always well suited to many problems, particularly when there is a need for real-time insights.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Enterprise networks are complex. Moreover, they were designed and deployed to meet a specific set of business requirements at a specific point in time. But, the adoption of cloud services, new business applications and intensifying security policies, among other factors, require IT organizations to continuously deploy configuration changes. Therefore, enterprises are looking for better ways to automate the management of their networks while still leveraging existing capabilities, optimizing perf...
"Software-defined storage is a big problem in this industry because so many people have different definitions as they see fit to use it," stated Peter McCallum, VP of Datacenter Solutions at FalconStor Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet a...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus...
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
Verizon Communications Inc. (NYSE, Nasdaq: VZ) and Yahoo! Inc. (Nasdaq: YHOO) have entered into a definitive agreement under which Verizon will acquire Yahoo's operating business for approximately $4.83 billion in cash, subject to customary closing adjustments. Yahoo informs, connects and entertains a global audience of more than 1 billion monthly active users** -- including 600 million monthly active mobile users*** through its search, communications and digital content products. Yahoo also co...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
As companies gain momentum, the need to maintain high quality products can outstrip their development team’s bandwidth for QA. Building out a large QA team (whether in-house or outsourced) can slow down development and significantly increases costs. This eBook takes QA profiles from 5 companies who successfully scaled up production without building a large QA team and includes: What to consider when choosing CI/CD tools How culture and communication can make or break implementation